Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$322K Buy
7,549
+554
+8% +$24.8K 0.09% 185
2026
Q1
$337K Buy
6,995
+1,649
+31% +$76.9K 0.11% 184
2025
Q4
$259K Sell
5,346
-6
-0.1% -$297 0.09% 209
2025
Q3
$253K Sell
5,352
-1,057
-16% -$51K 0.09% 209
2025
Q2
$310K Buy
6,409
+1,035
+19% +$52.9K 0.12% 162
2025
Q1
$298K Buy
5,374
+636
+13% +$34.4K 0.16% 122
2024
Q4
$229K Buy
4,738
+85
+2% +$4.32K 0.11% 162
2024
Q3
$268K Sell
4,653
-11
-0.2% -$594 0.22% 116
2024
Q2
$226K Buy
+4,664
New +$225K 0.15% 133

Other funds holding SNY

Sunpointe's SNY Position: Q2 2026 in Review

Sunpointe increased its Sanofi (SNY) stake by 7.9% in Q2 2026, buying an estimated $24.8K and bringing the position to 7,549 shares worth $322K. The position accounts for 0.09% of the portfolio, ranked #185.

Sunpointe first reported a position in SNY in Q2 2024 and has held it in 9 quarters since. The position peaked at $337K in Q1 2026. 716 funds tracked by Wall St. Rank hold SNY as of Q2 2026.

  • Sunpointe held 7,549 shares of Sanofi worth $322K as of Q2 2026.
  • Sunpointe bought 554 Sanofi shares in Q2 2026, an estimated $24.8K.
  • Sanofi made up 0.09% of Sunpointe's portfolio in Q2 2026, its #185 holding.
  • Sunpointe first reported a position in Sanofi in Q2 2024 and has held it in 9 quarters since.
  • Sunpointe's Sanofi position peaked at $337K in Q1 2026.
  • 716 funds tracked by Wall St. Rank held Sanofi as of Q2 2026.

Based on Sunpointe's 13F filing for Q2 2026, filed 24 Jul 2026.